Breaking News

Parexel, Palantir Expand AI Alliance

Aims to accelerate clinical data delivery and power clinical outcomes.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Parexel, a CRO providing the full range of Phase I to IV clinical development services, and Palantir Technologies Inc., a builder of Artificial Intelligence (AI) systems, entered a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for biopharmaceutical customers. 
 
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year.
 
Supported by Palantir’s software, Parexel’s clinical data platform provides an integrated digital environment to quickly automate manual processes, promote data discoverability, distill insights from historical trials and streamline coordination among scientific and operational teams and their partners. Incorporating Foundry and AIP into the Parexel environment will provide Parexel’s customers real-time access to validated data, ensuring transparency during studies with the goal of condensed timelines from trial planning to submission.
 
“We’re thrilled to expand our collaboration with Palantir — a leader in artificial intelligence technology — as we build on our application of AI to further improve clinical trial execution and advance our offerings in Real World Evidence, advanced analytics and Health Outcomes,” said Jonathan Shough, Chief Information Officer for Parexel. “Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or in various stages of development that demonstrate our commitment to be a fully digital CRO.”
 
“Parexel has embraced the principles of digital transformation using generative AI at remarkable speed and scale,” said Dr. Lalarukh Haris Shaikh, Executive, Life Sciences at Palantir. “The company will significantly accelerate its business by untapping the value of data via an ontology constructed within Palantir Foundry and connecting it to the immense power of generative AI in AIP. We are delighted to deepen our exceptional collaboration with Parexel, empowering them to fully leverage the capabilities of AIP and Foundry throughout their clinical processes and business operations.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters